More from News

subscribe

HBHL Symposium 2022 showcases innovative research

On May 19 and 20, Healthy Brains, Healthy Lives (HBHL) welcomed over 150 attendees to the first HBHL Symposium since 2019. Held at the Jeanne Timmins Amphitheatre at the Neuro (Montreal Neurological Institute-Hospital), the HBHL Symposium 2022 featured two days of talks and networking opportunities.

Published: 6 Jun 2022

HBHL contributes funding to VAST Platform

Earlier this year, the Government of Canada and its partners announced that they will invest $31.1 million over six years to support the training and development of students and early career researchers. The Health Research Training Platform (HRTP) will form 17 collaborative health research teams of participants across Canada with the goal of increasing their career prospects and building on Canadian research capacity at large.

Published: 28 Apr 2022

Winners announced for HBHL Neuro Commercialization Ignite Grants Competition III

HBHL is proud to officially announce the 10 winners of the third round of HBHL Ignite grants. The winning principle investigators and their respective projects are:

 

Published: 1 Apr 2022

HBHL-funded lab publishes promising study of free online intervention for schizophrenia

An HBHL-funded lab at the Douglas Research Centre, led by Martin Lepage, Professor of Psychiatry at McGill University and Deputy Scientific Director at the Douglas, has recently published a study in JAMA Psychiatry to determine the effectiveness of metacognitive training for psychosis (MCT) in treating individuals living with schizophrenia.

Published: 25 Mar 2022

HBHL funds largest study of its kind on psychedelics and the brain

A team of researchers from The Neuro (Montreal Neurological Institute-Hospital) and the Department of Biomedical Engineering of McGill University, the Broad Institute at Harvard/MIT, SUNY Downstate Health Sciences University and Mila – Quebec Artificial Intelligence Institute have shown how drug-induced changes in subjective awareness are linked to specific neurotransmitter receptor systems in the largest study of its kind on psychedelics and the brain, funded by HBHL. 

Published: 25 Mar 2022

Neurosphere involved in a new project with Neurasic Therapeutics, CQDM and Louise and Alan Edwards Foundation

NeuroSphere is pleased to continue to support Neurasic Therapeutics and Dr. Philippe Séguéla since our involvement in the launch of Neurasic therapeutics in 2020 and announce a new $965,000 collaboration between Neurasic Therapeutics, CQDM, the Louise and Alan Edwards Foundation, and Neurosphere.

Published: 13 Jan 2022

Update from HBHL on Equity, Diversity and Inclusion (December 2021)

Dear Healthy Brains, Healthy Lives Community,

Published: 7 Dec 2021

NeuroHub connection to UK Biobank facilitates recent publication

A new paper from researchers Jérôme Dockès Gaël Varoquaux and Jean-Baptiste Poline (Healthy Brains, Healthy Lives and NeuroDataScience ORIGAMI laboratory) explores generalization of machine learning algorithms using data from the UK Biobank and the impact of strategies to improve the performance of predicting biomarkers on new cohorts.

Published: 28 Oct 2021

HBHL Statement: National Day for Truth and Reconciliation

Dear Healthy Brains, Healthy Lives community,

Only 23 years ago, Canada closed Kivalliq Hall in Rankin Inlet. It was the last of 140 federally-run Indian Residential Schools created to deliberately and systematically destroy the languages, cultures and sovereignty of First Nations, Inuit and Métis people.

Published: 30 Sep 2021

Neuro Commercialization Grants: Accelerate Applications Now Open

Applications for the Accelerate Grants are now open for those HBHL-funded researchers whose projects have successfully completed the Ignite Phase of the Neuro Commercialization Grants. The NeuroSphere team will be in touch with researchers whose projects have been determined by the HBHL Innovation Committee to be ready to move on to the Accelerate phase.

Published: 15 Jul 2021

NeuroSphere-supported collaboration to develop new treatments for ALS

A new $1.7M collaboration between McGill University, Raya Therapeutic (Montreal) and Eikonizo Therapeutics (Cambridge, Massachusetts) will enable researchers to conduct clinical trials to assess the efficacy of six different drug candidates for the treatment of Amyotrophic Lateral Sclerosis (ALS).

Published: 21 Jun 2021

Launch of McGill-Douglas – Max Planck Institute of Psychiatry International Collaborative Initiative in Adversity and Mental Health

Announced today, the McGill-Douglas – Max Planck Institute of Psychiatry International Collaborative Initiative in Adversity and Mental Health is the first international effort devoted to understanding the biology behind how early-life adversity can increase the risk of psychiatric disorders over the course of an individual’s life.

Published: 11 May 2021

NeuroSphere Announces New Ignite Grant Recipients

NeuroSphere, McGill’s neuroscience innovation accelerator, is pleased to announce the 12 award recipients from its second Ignite Grant Competition.

Published: 19 Mar 2021

Pages

Back to top